QUICKLINKS AND VIEW OPITONS
5% more people given PCSK9 inhibitor evolocumab (Repatha) died from cardiovascular causes
Monday, March 20, 2017 12:41 pm Email this article
5% more people given the PCSK9 inhibitor evolocumab (Repatha) to lower cholesterol levels died from cardiovascular causes during an average follow-up of 2.2 years than those given a placebo according to the FOURIER trial.
251 people (out of 13,784) given evolocumab died compared to 240 people (out of 13,780) given a placebo.
So they want me to take a drug that you have to inject that costs $14,000 per year that increases my chance of dying?
No, thank you.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, and Pedersen TR. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017 Mar 17; on-line.
Author’s Contact Info
TIMI Study Group
Division of Cardiovascular Medicine
Brigham and Women’s Hospital
60 Fenwood Rd
Boston, MA 02115 USA
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.